ConVerd's First Oncolytic Vaccinia Virus Product hV01 Advances to Phase II Clinical Study

October 29, 2024 – ConVerd's first oncolytic vaccinia virus product, hV01, has received approval from the Medical Ethics Committee of Zhejiang Provincial People's Hospital, marking the initiation of its Phase IIa clinical study. The study will be conducted by the Department of Medical Oncology at Zhejiang Provincial People's Hospital, with Professor Zhiquan Qin serving as the Principal Investigator (PI). The clinical trial information was first disclosed on the Drug Clinical Trial Registration and Information Disclosure Platform on November 13, 2024, and subsequently filed for international collaborative clinical trial approval in the Human Genetic Resources Management Service System on January 24, 2025.

Professor Zhiquan Qin, currently Chief Physician of Medical Oncology at Zhejiang Provincial People's Hospital, brings 30 years of clinical oncology experience, specializing in comprehensive treatments for lung cancer, primary liver cancer, gastrointestinal malignancies, breast cancer, and renal cancer, including chemotherapy, immunotherapy, and targeted therapy. He also serves as a committee member of the Multidisciplinary Diagnosis Working Group of the Tumor Marker Professional Committee, Chinese Anti-Cancer Association, and the Zhejiang Medical Doctor Association Oncology Branch.